http://www.streetinsider.com Latest StreetInsider.com News Articles en-us Copyright 2026, StreetInsider.com rss@streetinsider.com (SI RSS) rss@streetinsider.com (SI RSS) Fri, 28 Aug 2026 17:26:00 -0400 http://blogs.law.harvard.edu/tech/rss http://www.streetinsider.com/images/rss_logo.gif http://www.streetinsider.com 143 28 0 1 2 3 21 22 23 Saturday Sunday http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++Spero+Therapeutics%2C+Inc.++For%3A+Aug+28/26999170.html si-local-file:///var/storage/secattach/20260828/26999170.html http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++Spero+Therapeutics%2C+Inc.++For%3A+Aug+28/26999170.html Fri, 28 Aug 2026 17:26:00 -0400 O.30518154 SPRO http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++Spero+Therapeutics%2C+Inc.++For%3A+Aug+28/26999170.html si-local-file:///var/storage/secattach/20260828/26999170.html http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++Spero+Therapeutics%2C+Inc.++For%3A+Aug+28/26999170.html Fri, 28 Aug 2026 17:26:00 -0400 O.30518154 SPRO http://www.streetinsider.com/SEC+Filings/Form++S-3++++++++Spero+Therapeutics%2C+Inc.+++++++++++++/26998952.html si-local-file:///var/storage/secattach/20260828/26998952.html http://www.streetinsider.com/SEC+Filings/Form++S-3++++++++Spero+Therapeutics%2C+Inc.+++++++++++++/26998952.html Fri, 28 Aug 2026 17:04:00 -0400 O.30518154 SPRO http://www.streetinsider.com/SEC+Filings/Form++S-3++++++++Spero+Therapeutics%2C+Inc.+++++++++++++/26998952.html si-local-file:///var/storage/secattach/20260828/26998952.html http://www.streetinsider.com/SEC+Filings/Form++S-3++++++++Spero+Therapeutics%2C+Inc.+++++++++++++/26998952.html Fri, 28 Aug 2026 17:04:00 -0400 O.30518154 SPRO http://www.streetinsider.com/Earnings/SmartPros+Ltd.+%28SPRO%29+Tops+Q2+EPS+by+1c/26913679.html <p>SmartPros Ltd. (NASDAQ: SPRO) reported Q2 EPS of ($0.16), $0.01 better than the analyst estimate of ($0.17).</p><p>For earnings history and earnings-related data on SmartPros Ltd. (SPRO) <a href="http://www.streetinsider.com/ec_earnings.php?q=SPRO">click here</a>.</p> http://www.streetinsider.com/Earnings/SmartPros+Ltd.+%28SPRO%29+Tops+Q2+EPS+by+1c/26913679.html Wed, 12 Aug 2026 16:41:03 -0400 SPRO http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++Spero+Therapeutics%2C+Inc.++For%3A+Aug+12/26912899.html si-local-file:///var/storage/secattach/20260812/26912899.html http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++Spero+Therapeutics%2C+Inc.++For%3A+Aug+12/26912899.html Wed, 12 Aug 2026 16:09:00 -0400 O.30518154 SPRO http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++Spero+Therapeutics%2C+Inc.++For%3A+Aug+12/26912899.html si-local-file:///var/storage/secattach/20260812/26912899.html http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++Spero+Therapeutics%2C+Inc.++For%3A+Aug+12/26912899.html Wed, 12 Aug 2026 16:09:00 -0400 O.30518154 SPRO http://www.streetinsider.com/SEC+Filings/Form++10-Q+++++++Spero+Therapeutics%2C+Inc.++For%3A+Jun+30/26912640.html si-local-file:///var/storage/secattach/20260812/26912640.html http://www.streetinsider.com/SEC+Filings/Form++10-Q+++++++Spero+Therapeutics%2C+Inc.++For%3A+Jun+30/26912640.html Wed, 12 Aug 2026 16:03:00 -0400 O.30518154 SPRO http://www.streetinsider.com/SEC+Filings/Form++10-Q+++++++Spero+Therapeutics%2C+Inc.++For%3A+Jun+30/26912640.html si-local-file:///var/storage/secattach/20260812/26912640.html http://www.streetinsider.com/SEC+Filings/Form++10-Q+++++++Spero+Therapeutics%2C+Inc.++For%3A+Jun+30/26912640.html Wed, 12 Aug 2026 16:03:00 -0400 O.30518154 SPRO http://www.streetinsider.com/Press+Releases/Spero+Therapeutics+Announces+Second+Quarter+2026+Operating+Results+and+Provides+Business+Update/26912545.html <ul><li><em>Entered an exclusive license agreement with Innovent Biologics for SP001, a Phase 2-ready, third-generation anti-CD40L antibody for immune-mediated diseases </em></li><li><em>U.S. Food and Drug Administration approved Utebzi™ (tebipenem pivoxil), the first and only oral carbapenem antibiotic for adults with complicated urinary tract infections (cUTIs), including pyelonephritis</em></li><li><em>Closed $105 million non-recourse, non-dilutive financing backed by a portion of future Utebzi milestones and royalties, extending cash runway into the second half of 2029</em></li><li><em>Appointed Debra Zack, M.D., Ph.D., as Chief Medical Officer</em></li><li><em>Conference call today at 5pm EDT</em><br/></li></ul> <p>CAMBRIDGE, Mass., Aug. 12, 2026 (GLOBE NEWSWIRE) -- <a target="_blank" href="https://www.globenewswire.com/Tracker?data=W1DlfOHlVyo8YzCg2TmppyjFbxzTUt00MIsZjOFdaAuYC4nB9yYp-jy9dgkB7UrMbwTWJQzeC0qeCyueBFcZbZIoVOx7NYP9Oq8YAyoM4jE=" rel="nofollow" target="_blank">Spero Therapeutics, Inc.</a> (Nasdaq: http://www.streetinsider.com/Press+Releases/Spero+Therapeutics+Announces+Second+Quarter+2026+Operating+Results+and+Provides+Business+Update/26912545.html Wed, 12 Aug 2026 16:01:00 -0400 A.06822034 O.20026344 O.30518154 SPRO http://www.streetinsider.com/Press+Releases/Spero+Therapeutics+Announces+Second+Quarter+2026+Operating+Results+and+Provides+Business+Update/26912545.html <ul><li><em>Entered an exclusive license agreement with Innovent Biologics for SP001, a Phase 2-ready, third-generation anti-CD40L antibody for immune-mediated diseases </em></li><li><em>U.S. Food and Drug Administration approved Utebzi™ (tebipenem pivoxil), the first and only oral carbapenem antibiotic for adults with complicated urinary tract infections (cUTIs), including pyelonephritis</em></li><li><em>Closed $105 million non-recourse, non-dilutive financing backed by a portion of future Utebzi milestones and royalties, extending cash runway into the second half of 2029</em></li><li><em>Appointed Debra Zack, M.D., Ph.D., as Chief Medical Officer</em></li><li><em>Conference call today at 5pm EDT</em><br/></li></ul> <p>CAMBRIDGE, Mass., Aug. 12, 2026 (GLOBE NEWSWIRE) -- <a target="_blank" href="https://www.globenewswire.com/Tracker?data=W1DlfOHlVyo8YzCg2TmppyjFbxzTUt00MIsZjOFdaAuYC4nB9yYp-jy9dgkB7UrMbwTWJQzeC0qeCyueBFcZbZIoVOx7NYP9Oq8YAyoM4jE=" rel="nofollow" target="_blank">Spero Therapeutics, Inc.</a> (Nasdaq: http://www.streetinsider.com/Press+Releases/Spero+Therapeutics+Announces+Second+Quarter+2026+Operating+Results+and+Provides+Business+Update/26912545.html Wed, 12 Aug 2026 16:01:00 -0400 A.06822034 O.20026344 O.30518154 SPRO http://www.streetinsider.com/Press+Releases/Spero+Therapeutics+Announces+Second+Quarter+2026+Operating+Results+and+Provides+Business+Update/26912545.html <ul><li><em>Entered an exclusive license agreement with Innovent Biologics for SP001, a Phase 2-ready, third-generation anti-CD40L antibody for immune-mediated diseases </em></li><li><em>U.S. Food and Drug Administration approved Utebzi™ (tebipenem pivoxil), the first and only oral carbapenem antibiotic for adults with complicated urinary tract infections (cUTIs), including pyelonephritis</em></li><li><em>Closed $105 million non-recourse, non-dilutive financing backed by a portion of future Utebzi milestones and royalties, extending cash runway into the second half of 2029</em></li><li><em>Appointed Debra Zack, M.D., Ph.D., as Chief Medical Officer</em></li><li><em>Conference call today at 5pm EDT</em><br/></li></ul> <p>CAMBRIDGE, Mass., Aug. 12, 2026 (GLOBE NEWSWIRE) -- <a target="_blank" href="https://www.globenewswire.com/Tracker?data=W1DlfOHlVyo8YzCg2TmppyjFbxzTUt00MIsZjOFdaAuYC4nB9yYp-jy9dgkB7UrMbwTWJQzeC0qeCyueBFcZbZIoVOx7NYP9Oq8YAyoM4jE=" rel="nofollow" target="_blank">Spero Therapeutics, Inc.</a> (Nasdaq: http://www.streetinsider.com/Press+Releases/Spero+Therapeutics+Announces+Second+Quarter+2026+Operating+Results+and+Provides+Business+Update/26912545.html Wed, 12 Aug 2026 16:01:00 -0400 A.06822034 O.20026344 O.30518154 SPRO http://www.streetinsider.com/Press+Releases/Spero+Therapeutics+Announces+Second+Quarter+2026+Operating+Results+and+Provides+Business+Update/26912545.html <ul><li><em>Entered an exclusive license agreement with Innovent Biologics for SP001, a Phase 2-ready, third-generation anti-CD40L antibody for immune-mediated diseases </em></li><li><em>U.S. Food and Drug Administration approved Utebzi™ (tebipenem pivoxil), the first and only oral carbapenem antibiotic for adults with complicated urinary tract infections (cUTIs), including pyelonephritis</em></li><li><em>Closed $105 million non-recourse, non-dilutive financing backed by a portion of future Utebzi milestones and royalties, extending cash runway into the second half of 2029</em></li><li><em>Appointed Debra Zack, M.D., Ph.D., as Chief Medical Officer</em></li><li><em>Conference call today at 5pm EDT</em><br/></li></ul> <p>CAMBRIDGE, Mass., Aug. 12, 2026 (GLOBE NEWSWIRE) -- <a target="_blank" href="https://www.globenewswire.com/Tracker?data=W1DlfOHlVyo8YzCg2TmppyjFbxzTUt00MIsZjOFdaAuYC4nB9yYp-jy9dgkB7UrMbwTWJQzeC0qeCyueBFcZbZIoVOx7NYP9Oq8YAyoM4jE=" rel="nofollow" target="_blank">Spero Therapeutics, Inc.</a> (Nasdaq: http://www.streetinsider.com/Press+Releases/Spero+Therapeutics+Announces+Second+Quarter+2026+Operating+Results+and+Provides+Business+Update/26912545.html Wed, 12 Aug 2026 16:01:00 -0400 A.06822034 O.20026344 O.30518154 SPRO http://www.streetinsider.com/Globe+Newswire/Spero+Therapeutics+Announces+Second+Quarter+2026+Operating+Results+and+Provides+Business+Update/26912545.html <ul><li><em>Entered an exclusive license agreement with Innovent Biologics for SP001, a Phase 2-ready, third-generation anti-CD40L antibody for immune-mediated diseases </em></li><li><em>U.S. Food and Drug Administration approved Utebzi™ (tebipenem pivoxil), the first and only oral carbapenem antibiotic for adults with complicated urinary tract infections (cUTIs), including pyelonephritis</em></li><li><em>Closed $105 million non-recourse, non-dilutive financing backed by a portion of future Utebzi milestones and royalties, extending cash runway into the second half of 2029</em></li><li><em>Appointed Debra Zack, M.D., Ph.D., as Chief Medical Officer</em></li><li><em>Conference call today at 5pm EDT</em><br/></li></ul> <p>CAMBRIDGE, Mass., Aug. 12, 2026 (GLOBE NEWSWIRE) -- <a target="_blank" href="https://www.globenewswire.com/Tracker?data=W1DlfOHlVyo8YzCg2TmppyjFbxzTUt00MIsZjOFdaAuYC4nB9yYp-jy9dgkB7UrMbwTWJQzeC0qeCyueBFcZbZIoVOx7NYP9Oq8YAyoM4jE=" rel="nofollow" target="_blank">Spero Therapeutics, Inc.</a> (Nasdaq: http://www.streetinsider.com/Globe+Newswire/Spero+Therapeutics+Announces+Second+Quarter+2026+Operating+Results+and+Provides+Business+Update/26912545.html Wed, 12 Aug 2026 16:01:00 -0400 A.06822034 O.20026344 O.30518154 SPRO http://www.streetinsider.com/Globe+Newswire/Spero+Therapeutics+Announces+Second+Quarter+2026+Operating+Results+and+Provides+Business+Update/26912545.html <ul><li><em>Entered an exclusive license agreement with Innovent Biologics for SP001, a Phase 2-ready, third-generation anti-CD40L antibody for immune-mediated diseases </em></li><li><em>U.S. Food and Drug Administration approved Utebzi™ (tebipenem pivoxil), the first and only oral carbapenem antibiotic for adults with complicated urinary tract infections (cUTIs), including pyelonephritis</em></li><li><em>Closed $105 million non-recourse, non-dilutive financing backed by a portion of future Utebzi milestones and royalties, extending cash runway into the second half of 2029</em></li><li><em>Appointed Debra Zack, M.D., Ph.D., as Chief Medical Officer</em></li><li><em>Conference call today at 5pm EDT</em><br/></li></ul> <p>CAMBRIDGE, Mass., Aug. 12, 2026 (GLOBE NEWSWIRE) -- <a target="_blank" href="https://www.globenewswire.com/Tracker?data=W1DlfOHlVyo8YzCg2TmppyjFbxzTUt00MIsZjOFdaAuYC4nB9yYp-jy9dgkB7UrMbwTWJQzeC0qeCyueBFcZbZIoVOx7NYP9Oq8YAyoM4jE=" rel="nofollow" target="_blank">Spero Therapeutics, Inc.</a> (Nasdaq: http://www.streetinsider.com/Globe+Newswire/Spero+Therapeutics+Announces+Second+Quarter+2026+Operating+Results+and+Provides+Business+Update/26912545.html Wed, 12 Aug 2026 16:01:00 -0400 A.06822034 O.20026344 O.30518154 SPRO http://www.streetinsider.com/Globe+Newswire/Spero+Therapeutics+Announces+Second+Quarter+2026+Operating+Results+and+Provides+Business+Update/26912545.html <ul><li><em>Entered an exclusive license agreement with Innovent Biologics for SP001, a Phase 2-ready, third-generation anti-CD40L antibody for immune-mediated diseases </em></li><li><em>U.S. Food and Drug Administration approved Utebzi™ (tebipenem pivoxil), the first and only oral carbapenem antibiotic for adults with complicated urinary tract infections (cUTIs), including pyelonephritis</em></li><li><em>Closed $105 million non-recourse, non-dilutive financing backed by a portion of future Utebzi milestones and royalties, extending cash runway into the second half of 2029</em></li><li><em>Appointed Debra Zack, M.D., Ph.D., as Chief Medical Officer</em></li><li><em>Conference call today at 5pm EDT</em><br/></li></ul> <p>CAMBRIDGE, Mass., Aug. 12, 2026 (GLOBE NEWSWIRE) -- <a target="_blank" href="https://www.globenewswire.com/Tracker?data=W1DlfOHlVyo8YzCg2TmppyjFbxzTUt00MIsZjOFdaAuYC4nB9yYp-jy9dgkB7UrMbwTWJQzeC0qeCyueBFcZbZIoVOx7NYP9Oq8YAyoM4jE=" rel="nofollow" target="_blank">Spero Therapeutics, Inc.</a> (Nasdaq: http://www.streetinsider.com/Globe+Newswire/Spero+Therapeutics+Announces+Second+Quarter+2026+Operating+Results+and+Provides+Business+Update/26912545.html Wed, 12 Aug 2026 16:01:00 -0400 A.06822034 O.20026344 O.30518154 SPRO http://www.streetinsider.com/Globe+Newswire/Spero+Therapeutics+Announces+Second+Quarter+2026+Operating+Results+and+Provides+Business+Update/26912545.html <ul><li><em>Entered an exclusive license agreement with Innovent Biologics for SP001, a Phase 2-ready, third-generation anti-CD40L antibody for immune-mediated diseases </em></li><li><em>U.S. Food and Drug Administration approved Utebzi™ (tebipenem pivoxil), the first and only oral carbapenem antibiotic for adults with complicated urinary tract infections (cUTIs), including pyelonephritis</em></li><li><em>Closed $105 million non-recourse, non-dilutive financing backed by a portion of future Utebzi milestones and royalties, extending cash runway into the second half of 2029</em></li><li><em>Appointed Debra Zack, M.D., Ph.D., as Chief Medical Officer</em></li><li><em>Conference call today at 5pm EDT</em><br/></li></ul> <p>CAMBRIDGE, Mass., Aug. 12, 2026 (GLOBE NEWSWIRE) -- <a target="_blank" href="https://www.globenewswire.com/Tracker?data=W1DlfOHlVyo8YzCg2TmppyjFbxzTUt00MIsZjOFdaAuYC4nB9yYp-jy9dgkB7UrMbwTWJQzeC0qeCyueBFcZbZIoVOx7NYP9Oq8YAyoM4jE=" rel="nofollow" target="_blank">Spero Therapeutics, Inc.</a> (Nasdaq: http://www.streetinsider.com/Globe+Newswire/Spero+Therapeutics+Announces+Second+Quarter+2026+Operating+Results+and+Provides+Business+Update/26912545.html Wed, 12 Aug 2026 16:01:00 -0400 A.06822034 O.20026344 O.30518154 SPRO http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Spero+Therapeutics%2C+Inc.++For%3A+Aug+03++Filed+by%3A+Zack+Debra/26910787.html si-local-file:///var/storage/secattach/20260812/26910787.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Spero+Therapeutics%2C+Inc.++For%3A+Aug+03++Filed+by%3A+Zack+Debra/26910787.html Wed, 12 Aug 2026 11:03:00 -0400 O.30518154 SPRO http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Spero+Therapeutics%2C+Inc.++For%3A+Aug+03++Filed+by%3A+Zack+Debra/26910787.html si-local-file:///var/storage/secattach/20260812/26910787.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Spero+Therapeutics%2C+Inc.++For%3A+Aug+03++Filed+by%3A+Zack+Debra/26910787.html Wed, 12 Aug 2026 11:03:00 -0400 O.30518154 SPRO http://www.streetinsider.com/SEC+Filings/Form++3++++++++++Spero+Therapeutics%2C+Inc.++For%3A+Aug+03++Filed+by%3A+Zack+Debra/26910816.html si-local-file:///var/storage/secattach/20260812/26910816.html http://www.streetinsider.com/SEC+Filings/Form++3++++++++++Spero+Therapeutics%2C+Inc.++For%3A+Aug+03++Filed+by%3A+Zack+Debra/26910816.html Wed, 12 Aug 2026 11:03:00 -0400 O.30518154 SPRO http://www.streetinsider.com/SEC+Filings/Form++3++++++++++Spero+Therapeutics%2C+Inc.++For%3A+Aug+03++Filed+by%3A+Zack+Debra/26910816.html si-local-file:///var/storage/secattach/20260812/26910816.html http://www.streetinsider.com/SEC+Filings/Form++3++++++++++Spero+Therapeutics%2C+Inc.++For%3A+Aug+03++Filed+by%3A+Zack+Debra/26910816.html Wed, 12 Aug 2026 11:03:00 -0400 O.30518154 SPRO http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Spero+Therapeutics%2C+Inc.++For%3A+Aug+03++Filed+by%3A+Zack+Debra/26885952.html si-local-file:///var/storage/secattach/20260806/26885952.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Spero+Therapeutics%2C+Inc.++For%3A+Aug+03++Filed+by%3A+Zack+Debra/26885952.html Thu, 06 Aug 2026 18:49:00 -0400 O.30518154 SPRO http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Spero+Therapeutics%2C+Inc.++For%3A+Aug+03++Filed+by%3A+Zack+Debra/26885952.html si-local-file:///var/storage/secattach/20260806/26885952.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Spero+Therapeutics%2C+Inc.++For%3A+Aug+03++Filed+by%3A+Zack+Debra/26885952.html Thu, 06 Aug 2026 18:49:00 -0400 O.30518154 SPRO http://www.streetinsider.com/SEC+Filings/Form++3++++++++++Spero+Therapeutics%2C+Inc.++For%3A+Aug+03++Filed+by%3A+Zack+Debra/26885938.html si-local-file:///var/storage/secattach/20260806/26885938.html http://www.streetinsider.com/SEC+Filings/Form++3++++++++++Spero+Therapeutics%2C+Inc.++For%3A+Aug+03++Filed+by%3A+Zack+Debra/26885938.html Thu, 06 Aug 2026 18:42:00 -0400 O.30518154 SPRO http://www.streetinsider.com/SEC+Filings/Form++3++++++++++Spero+Therapeutics%2C+Inc.++For%3A+Aug+03++Filed+by%3A+Zack+Debra/26885938.html si-local-file:///var/storage/secattach/20260806/26885938.html http://www.streetinsider.com/SEC+Filings/Form++3++++++++++Spero+Therapeutics%2C+Inc.++For%3A+Aug+03++Filed+by%3A+Zack+Debra/26885938.html Thu, 06 Aug 2026 18:42:00 -0400 O.30518154 SPRO